{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:39:39Z","timestamp":1790746779037,"version":"4.1.0"},"reference-count":34,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"vor","delay-in-days":23,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["eJHaem"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Primary myelofibrosis (MF) is characterized by MF, splenomegaly, and extramedullary hematopoiesis. MF initially presents with reticular fibers (RFs) and progresses to increased collagen fiber deposition in the advanced stages. Although recent clinical trials have adopted MF improvement as an evaluation criterion, current diagnostic methods rely primarily on qualitative assessments based on the presence or absence of reticular and collagen fibers. Therefore, detecting subtle changes during the early stages of MF can be challenging.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We developed a novel deep learning\u2010based method for quantitatively evaluating MF by measuring RFs as an indicator. Unlike collagen fibers, RFs are detectable from the early stages of MF and increase as the disease progresses. Moreover, based on the hypothesis that splenic fibrosis progresses in parallel with MF, we applied this method to evaluate RFs in the spleen. Using these methods, we analyzed temporal changes in fibrosis, splenomegaly, and hematopoietic stem cell dynamics over time in two MF models: a drug\u2010induced fibrosis model using romiplostim and a\n                      <jats:italic>Jak2<\/jats:italic>\n                      V617F gene\u2013transformed mouse. Additionally, we examined correlations between our quantitative fibrosis measurements and clinical data, including MF grade and genetic mutations.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Our findings revealed that in\n                      <jats:italic>Jak2<\/jats:italic>\n                      V617F gene\u2013transformed mice, splenomegaly and extramedullary hematopoiesis in the spleen occurred earlier than MF. Furthermore, the quantitative fibrosis method significantly correlated with MF grade in patients with myeloproliferative neoplasms and the\n                      <jats:italic>JAK2<\/jats:italic>\n                      V617F mutant allele burden.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our novel deep learning\u2010based method successfully captured temporal changes in bone marrow and spleen fibrosis and shows potential for clinical application.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>The authors have confirmed clinical trial registration is not needed for this submission<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/jha2.70273","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T17:54:28Z","timestamp":1777053268000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Sequential Analysis of Murine Myelofibrosis Models Using a Novel Deep Learning\u2010Based Fibrosis Quantitative Method"],"prefix":"10.1002","volume":"7","author":[{"given":"Toshikuni","family":"Kawamura","sequence":"first","affiliation":[{"name":"Division of Hematology Department of Internal Medicine National Defense Medical College  Tokorozawa Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8611-0862","authenticated-orcid":false,"given":"Takaaki","family":"Maekawa","sequence":"additional","affiliation":[{"name":"Division of Hematology Department of Internal Medicine National Defense Medical College  Tokorozawa Saitama Japan"},{"name":"Division of Palliative Care National Defense Medical College Hospital  Tokorozawa Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keita","family":"Kouzu","sequence":"additional","affiliation":[{"name":"Department of Surgery National Defense Medical College  Tokorozawa Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiraku","family":"Ogata","sequence":"additional","affiliation":[{"name":"Division of Hematology Department of Internal Medicine National Defense Medical College  Tokorozawa Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriaki","family":"Tachi","sequence":"additional","affiliation":[{"name":"Division of Hematology Department of Internal Medicine National Defense Medical College  Tokorozawa Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoichiro","family":"Kato","sequence":"additional","affiliation":[{"name":"Division of Hematology Department of Internal Medicine National Defense Medical College  Tokorozawa Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiko","family":"Osawa","sequence":"additional","affiliation":[{"name":"Division of Hematology Department of Internal Medicine National Defense Medical College  Tokorozawa Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Einama","sequence":"additional","affiliation":[{"name":"Department of Surgery National Defense Medical College  Tokorozawa Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimiya","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Basic Pathology National Defense Medical College  Tokorozawa Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Division of Hematology Department of Internal Medicine National Defense Medical College  Tokorozawa Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"key":"e_1_2_12_2_1","first-page":"39","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow S. H.","year":"2017"},{"key":"e_1_2_12_3_1","first-page":"1128","article-title":"European Consensus on Grading Bone Marrow Fibrosis and Assessment of Cellularity","volume":"90","author":"Thiele J.","year":"2005","journal-title":"Haematologica"},{"key":"e_1_2_12_4_1","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1200\/JCO.2017.76.4886","article-title":"MIPSS70: Mutation\u2010Enhanced International Prognostic Score System for Transplantation\u2010Age Patients With Primary Myelofibrosis","volume":"70","author":"Guglielmelli P.","year":"2018","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_12_5_1","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A Double\u2010Blind, Placebo\u2010Controlled Trial of Ruxolitinib for Myelofibrosis","volume":"366","author":"Verstovsek S.","year":"2012","journal-title":"New England Journal of Medicine"},{"key":"e_1_2_12_6_1","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK Inhibition With Ruxolitinib Versus Best Available Therapy for Myelofibrosis","volume":"366","author":"Harrison C.","year":"2012","journal-title":"New England Journal of Medicine"},{"key":"e_1_2_12_7_1","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/leu.2016.148","article-title":"Long\u2010Term Findings From COMFORT\u2010II, a Phase 3 Study of Ruxolitinib vs Best Available Therapy for Myelofibrosis","volume":"30","author":"Harrison C. N.","year":"2016","journal-title":"Leukemia"},{"key":"e_1_2_12_8_1","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1002\/cncr.34205","article-title":"Defining Disease Modification in Myelofibrosis in the Era of Targeted Therapy","volume":"128","author":"Pemmaraju N.","year":"2022","journal-title":"Cancer"},{"key":"e_1_2_12_9_1","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1200\/JCO.21.02188","article-title":"Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and Efficacy","volume":"40","author":"Harrison C. N.","year":"2022","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_12_10_1","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1200\/JCO.20.02864","article-title":"Randomized, Single\u2010Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis","volume":"39","author":"Mascarenhas J.","year":"2021","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_12_11_1","doi-asserted-by":"crossref","first-page":"e434","DOI":"10.1016\/S2352-3026(22)00116-8","article-title":"Addition of Navitoclax to Ongoing Ruxolitinib Treatment in Patients With Myelofibrosis (REFINE): A Post\u2010Hoc Analysis of Molecular Biomarkers in a Phase 2 Study","volume":"9","author":"Pemmaraju N.","year":"2022","journal-title":"Lancet Haematology"},{"key":"e_1_2_12_12_1","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/jha2.854","article-title":"Changes in Bone Marrow Fibrosis During Momelotinib or Ruxolitinib Therapy Do Not Correlate With Efficacy Outcomes in Patients With Myelofibrosis","volume":"5","author":"Oh S. T.","year":"2024","journal-title":"EJHaem"},{"key":"e_1_2_12_13_1","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.leukres.2010.01.005","article-title":"Quantification of Fibrosis and Osteosclerosis in Myeloproliferative Neoplasms: A Computer\u2010Assisted Image Study","volume":"34","author":"Teman C. J.","year":"2010","journal-title":"Leukemia Research"},{"key":"e_1_2_12_14_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.14440\/jbm.2016.152","article-title":"Quantitative Histological Image Analyses of Reticulin Fibers in a Myelofibrotic Mouse","volume":"3","author":"A Lucero H.","year":"2016","journal-title":"Journal of Biological Methods"},{"key":"e_1_2_12_15_1","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/B978-0-7020-6864-5.00012-8","volume-title":"Bancroft's Theory and Practice of Histological Techniques","author":"Bancroft J. D.","year":"2019"},{"key":"e_1_2_12_16_1","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1111\/bjh.13343","article-title":"Transient Elastography Spleen Stiffness Measurements in Primary Myelofibrosis Patients: A Pilot Study in a Single Centre","volume":"170","author":"Iurlo A.","year":"2015","journal-title":"British Journal of Haematology"},{"key":"e_1_2_12_17_1","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1038\/leu.2017.112","article-title":"Myeloproliferative Leukemia Protein Activation Directly Induces Fibrocyte Differentiation to Cause Myelofibrosis","volume":"31","author":"Maekawa T.","year":"2017","journal-title":"Leukemia"},{"key":"e_1_2_12_18_1","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/sj.leu.2405043","article-title":"Development of ET, Primary Myelofibrosis and PV in Mice Expressing JAK2 V617F","volume":"22","author":"Shide K.","year":"2008","journal-title":"Leukemia"},{"key":"e_1_2_12_19_1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jim.2010.09.025","article-title":"Improved Serum\u2010Free Culture Conditions for Spleen\u2010Derived Murine Fibrocytes","volume":"363","author":"Crawford J. R.","year":"2010","journal-title":"Journal of Immunological Methods"},{"key":"e_1_2_12_20_1","first-page":"993","article-title":"Silver Impregnation of Reticulum in Paraffin Sections","volume":"13","author":"G\u00f6m\u00f6ri G.","year":"1937","journal-title":"American Journal of Pathology"},{"key":"e_1_2_12_21_1","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1182\/blood.2019000051","article-title":"Increased SLAMF7high Monocytes in Myelofibrosis Patients Harboring JAK2V617F Provide a Therapeutic Target of Elotuzumab","volume":"134","author":"Maekawa T.","year":"2019","journal-title":"Blood"},{"key":"e_1_2_12_22_1","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/s41375-021-01408-w","article-title":"Deep Learning Detects Acute Myeloid Leukemia and Predicts NPM1 Mutation Status From Bone Marrow Smears","volume":"36","author":"Eckardt J.\u2010N.","year":"2022","journal-title":"Leukemia"},{"key":"e_1_2_12_23_1","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-21887-w","article-title":"Deep Learning Application of the Discrimination of Bone Marrow Aspiration Cells in Patients With Myelodysplastic Syndromes","volume":"12","author":"Lee N.","year":"2022","journal-title":"Scientific Reports"},{"key":"e_1_2_12_24_1","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1038\/s41598-021-82826-9","article-title":"Automated Diagnostic Support System With Deep Learning Algorithms for Distinction of Philadelphia Chromosome\u2010Negative Myeloproliferative Neoplasms Using Peripheral Blood Specimen","volume":"11","author":"Kimura K.","year":"2021","journal-title":"Scientific Reports"},{"key":"e_1_2_12_25_1","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1111\/liv.14966","article-title":"Deep Learning for Noninvasive Liver Fibrosis Classification: A Systematic Review","volume":"41","author":"Anteby R.","year":"2021","journal-title":"Liver International"},{"key":"e_1_2_12_26_1","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/S2213-2600(20)30003-5","article-title":"Imaging Research in Fibrotic Lung Disease; Applying Deep Learning to Unsolved Problems","volume":"8","author":"Walsh S. L. F.","year":"2020","journal-title":"Lancet Respiratory Medicine"},{"key":"e_1_2_12_27_1","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1097\/PAT.0b013e3283613dbf","article-title":"Up\u2010Regulated Expression of CXCL12 in Human Spleens With Extramedullary Haematopoiesis","volume":"45","author":"Miwa Y.","year":"2013","journal-title":"Pathology"},{"key":"e_1_2_12_28_1","doi-asserted-by":"crossref","first-page":"54082","DOI":"10.18632\/oncotarget.10789","article-title":"CXCL12\/CXCR4 Pathway is Activated by Oncogenic JAK2 in a PI3K\u2010Dependent Manner","volume":"8","author":"Abdelouahab H.","year":"2016","journal-title":"Oncotarget"},{"key":"e_1_2_12_29_1","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/S0301-472X(02)00883-4","article-title":"Current Understanding of Stem Cell Mobilization","volume":"30","author":"Lapidot T.","year":"2002","journal-title":"Experimental Hematology"},{"key":"e_1_2_12_30_1","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/ni813","article-title":"G\u2010CSF Induces Stem Cell Mobilization by Decreasing Bone Marrow SDF\u20101 and Up\u2010Regulating CXCR4","volume":"3","author":"Petit I.","year":"2002","journal-title":"Nature Immunology"},{"key":"e_1_2_12_31_1","doi-asserted-by":"crossref","first-page":"898","DOI":"10.3390\/ijms19030898","article-title":"Understanding Splenomegaly in Myelofibrosis: Association With Molecular Pathogenesis","volume":"19","author":"Song M. K.","year":"2018","journal-title":"International Journal of Molecular Sciences"},{"key":"e_1_2_12_32_1","doi-asserted-by":"crossref","first-page":"8308","DOI":"10.1038\/s41598-018-26693-x","article-title":"Niche\u2010Induced Extramedullary Hematopoiesis in the Spleen is Regulated by the Transcription Factor Tlx1","volume":"8","author":"Oda A.","year":"2018","journal-title":"Scientific Reports"},{"key":"e_1_2_12_33_1","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s12185-014-1721-9","article-title":"Consequences of the JAK2V617F Allele Burden for the Prediction of Transformation Into Myelofibrosis From Polycythemia Vera and Essential Thrombocythemia","volume":"101","author":"Shirane S.","year":"2015","journal-title":"International Journal of Hematology"},{"key":"e_1_2_12_34_1","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/ajh.23676","article-title":"JAK2V617F Monitoring in Polycythemia Vera and Essential Thrombocythemia: Clinical Usefulness for Predicting Myelofibrotic Transformation and Thrombotic Events","volume":"89","author":"Alvarez\u2010Larr\u00e1n A.","year":"2014","journal-title":"American Journal of Hematology"},{"key":"e_1_2_12_35_1","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.thromres.2014.11.006","article-title":"The JAK2 V617F Mutational Status and Allele Burden May be Related With the Risk of Venous Thromboembolic Events in Patients With Philadelphia\u2010Negative Myeloproliferative Neoplasms","volume":"135","author":"Borowczyk M.","year":"2015","journal-title":"Thrombosis Research"}],"container-title":["eJHaem"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jha2.70273","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jha2.70273","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jha2.70273","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T17:16:18Z","timestamp":1777223778000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jha2.70273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1002\/jha2.70273"],"URL":"https:\/\/doi.org\/10.1002\/jha2.70273","archive":["Portico"],"relation":{},"ISSN":["2688-6146","2688-6146"],"issn-type":[{"value":"2688-6146","type":"print"},{"value":"2688-6146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"2026-01-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70273"}}